Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells

AML Collaborative Group, A systematic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haem 1998;103:100–9. Hande, 1998, Clinical applications of anticancer drugs targeted to topoisomerase II, Biochim. Biophys. Acta, 1400, 173, 10.1016/S0167-4781(98)00134-1 Jackson, 1997, The use of an oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy, Leukaemia, 11, 1193, 10.1038/sj.leu.2400726 Borchmann, 1997, Idarubicin: a brief overview on pharmacology and clinical use, Int. J. Clin. Pharmacol. Ther., 35, 80 Bogush, 1996, Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells, Anticancer Res., 16, 365 Manketkorn, 1996, Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, dainorubicin, 8-(S)-fluoroidarubicin and idarubicin in multidrug-resistant K562 cells, Mol. Pharmacol., 49, 532 Broxterman, 2000, P-glycoprotein in primary acute myeloid leukaemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy, Leukaemia, 14, 1018, 10.1038/sj.leu.2401796 Marbeuf-Gueye, 1999, Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein, Biochim. Biophys. Acta, 1450, 374, 10.1016/S0167-4889(99)00060-9 Wielinga, 2000, The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells, Eur. J. Biochem., 267, 649, 10.1046/j.1432-1327.2000.01030.x Binaschi, 1998, Human DNA topoisomerase IIα-dependent DNA cleavage and yeast cell killing by anthracycline analogues, Cancer Res., 58, 1886 Gerwirtz, 1999, A critical evaluation of the mechanisms of action proposed for the antitumour effects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem. Pharmacol., 57, 727, 10.1016/S0006-2952(98)00307-4 Austin, 1998, Eukaryotic DNA topoisomerase IIβ, Bioessays, 20, 215, 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q Zunino, 1990, DNA topoisomerase II as the primary target of antitumour anthracyclines, Anticancer Drug Design, 5, 307 Fortune, 2000, Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice, Prog. Nucl. Acid Res. Mol. Biol., 64, 221, 10.1016/S0079-6603(00)64006-0 Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi O, Hollard D, Faberes C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P. A prospective randomized trial of idarubicin vs. daunorubicin in combination chemotherapy for acute myelogenous leukaemia of the age group 55–75. Leukaemia 1996;10:389–95. Berman, 1991, Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukaemia, Blood, 77, 1666, 10.1182/blood.V77.8.1666.1666 Willmore, 1998, Etoposide targets topoisomerase IIα and IIβ in leukaemic cells: isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique, Mol. Pharmocol., 53, 78, 10.1124/mol.54.1.78 Gandhi, 1993, Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukaemia during therapy, J. Clin. Oncol., 11, 116, 10.1200/JCO.1993.11.1.116 Yang, 2000, DNA topoisomerase IIβ and neural development, Science, 287, 131, 10.1126/science.287.5450.131 Errington, 1999, Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation, Mol. Pharmacol., 56, 1309, 10.1124/mol.56.6.1309 Cowell, 1998, Nuclear distribution of human DNA topoisomerase IIβ: a nuclear targeting signal resides in the 116-residue C-terminal tail, Exp. Cell Res., 243, 232, 10.1006/excr.1998.4150 Moses, 1988, Synergistic enhancement of 6-thioguanine cytotoxicity by ADP-ribosyltransferase inhibitors, Cancer Res., 48, 5650 Boulton, 1995, Potentiation of temozolamide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors, Br. J. Cancer, 72, 849, 10.1038/bjc.1995.423 Frank, 1996, Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumour cells, Blood, 88, 977, 10.1182/blood.V88.3.977.977 Ishida, 1996, The combination of different types of antitumour topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule, Anticancer Res., 16, 2735 Jensen, 2000, A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines, J. Biol. Chem., 275, 2137, 10.1074/jbc.275.3.2137 Sehested, 1996, Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle, Biochem. Pharm., 51, 879, 10.1016/0006-2952(95)02241-4 Gieseler, 1994, Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding, Ann. Hematol., 69, s13, 10.1007/BF01757349 Kuffel, 1992, Anthracyclines and their C-13 metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture, Cancer Chemother. Pharmacol., 30, 51, 10.1007/BF00686485 Fukushima, 1999, Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells, Leukaemia Res., 23, 37, 10.1016/S0145-2126(98)00138-6 Gillies, 1987, Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer, Br. J. Clin. Pharmacol., 23, 303, 10.1111/j.1365-2125.1987.tb03049.x Binaschi, 1997, Relationships between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity, Mol. Pharmacol., 51, 1053, 10.1124/mol.51.6.1053 Meczes, 1997, Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast, Cancer Chemother. Pharmacol., 39, 367, 10.1007/s002800050585 Subramanian, 1998, Ultraviolet-induced DNA damage stimulates topoisomerase I–DNA complex formation in vivo: possible relationship with DNA repair, Cancer Res., 58, 976 Kaufmann, 1998, Cell death induced by topoisomerase-targeted drugs: more questions than answers, Biochim. Biophys. Acta, 1400, 195, 10.1016/S0167-4781(98)00136-5 Cornarotti, 1996, Drug sensitivity and sequence specificity of human recombinant DNA topoismerase IIα(p170) and IIβ(p180), Mol. Pharmacol., 50, 1463 Ross, 1995, Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance, Biochem. Pharmocol., 50, 1673, 10.1016/0006-2952(95)02069-1 Capranico, 1989, Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukaemia P388 cells, Cancer Res., 49, 2022 Zwelling, 1981, Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin, Biochemistry, 20, 6553, 10.1021/bi00526a006 Capranico, 1989, Formation, resealing and persistance of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukaemia cells, Chemico-Biol. Int., 72, 113, 10.1016/0009-2797(89)90022-7 Capranico, 1986, Single-strand DNA breaks induced by chromophore-modified anthracyclines in p388 leukaemia cells, Cancer Res., 46, 5499 Tewey, 1984, Intercalative antitumour drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II, J. Biol. Chem., 259, 9182, 10.1016/S0021-9258(17)47282-6